Impact of SGLT2 Inhibitors on Magnesium in Kidney Transplant Patients with and Without Diabetes
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26072904 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Carmine Secondulfo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, 84081 Baronissi, Italy. Hauptthemen laut MEDLINE: Kidney Transplantation, Magnesium, Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Magnesium (Mg2+) is essential for cardiovascular and metabolic health, yet hypomagnesemia is common in kidney transplant recipients (KTRs) due to immunosuppressive therapy and renal dysfunction. Oral Mg2+ supplementation is often ineffective due to poor absorption and side effects. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been shown to increase serum Mg2+ in chronic kidney disease, but their effects in KTRs, particularly patients without diabetes, remain unclear. This observational study assessed 63 KTRs treated with dapagliflozin, analyzing the serum Mg2+ levels at baseline and after 3 and 6 months. The hypomagnesemia prevalence, associations with oral supplementation, diabetes status, and diuretic use were evaluated. The results showed a significant Mg2+ increase with SGLT2i therapy, reducing hypomagnesemia regardless of the diabetes status. Oral supplementation did not correlate with improved Mg2+ levels, reinforcing its limited efficacy. Additional benefits included reductions in the body weight, blood pressure, and serum urate without compromising graft function. SGLT2i may offer a novel approach to managing hypomagnesemia in KTRs, potentially reducing the reliance on ineffective supplements while providing renal and cardiovascular benefits. Further research is needed to confirm these findings and elucidate the underlying mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, 84081 Baronissi, Italy.
- Department of Public Health, University of Naples "Federico II", 80131 Naples, Italy.
- Unit of Nephrology, Dialysis and Transplant, Salerno University Hospital "San Giovanni di Dio e Ruggi d'Aragona", 84131 Salerno, Italy.
ORCID-Profile: Carmine Secondulfo, Nicoletta Vecchione, Luca Apicella, Maria Amicone, Massimo Cirillo, Giancarlo Bilancio
Zitieren
APA
Secondulfo, C., Vecchione, N., Russo, D., Hamzeh, S., Iacuzzo, C., Apicella, L., Di Pietro, R. A., Pisani, A., Amicone, M., Cirillo, M., & Bilancio, G. (2025). Impact of SGLT2 Inhibitors on Magnesium in Kidney Transplant Patients with and Without Diabetes. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26072904
Vancouver
Secondulfo C, Vecchione N, Russo D, Hamzeh S, Iacuzzo C, Apicella L, et al. Impact of SGLT2 Inhibitors on Magnesium in Kidney Transplant Patients with and Without Diabetes. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26072904
BibTeX
@article{Secondulfo2025,
author = {Secondulfo, Carmine and Vecchione, Nicoletta and Russo, Dora and Hamzeh, Sarah and Iacuzzo, Candida and Apicella, Luca and Di Pietro, Renata Angela and Pisani, Antonio and Amicone, Maria and Cirillo, Massimo and Bilancio, Giancarlo},
title = {Impact of SGLT2 Inhibitors on Magnesium in Kidney Transplant Patients with and Without Diabetes},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26072904}
}
EUVIMED